**OTC Markets**

Joining us today is Dr. Andrea Small-Howard, the President Chief Scientific Officer of GB Sciences that trades on our OTCQB Venture Market under the ticker GBLX. GB Sciences is a plant inspired, biopharmaceutical research and development company creating patented disease targeted formulations of cannabis and other plant inspired therapeutic mixtures for the prescription drug market.

Andrea thanks so much for joining us today.

**Andrea Small-Howard**

And thank you for the opportunity to talk a little bit about GB Sciences today.

**OTC Markets**

Absolutely, so tell us a little about your background and how you got involved in the industry.

**Andrea Small-Howard**

Well I'm a biochemist by training and um I've always had an interest in plant-based medicines I don't know if you know this but according to the World Health Organization, greater than 80% of the world is still using traditional medicines that are largely plant based and my thought was you know when you're making new drugs, why don't you look to things that are already working for people right, but in a different format. So that's sort of the insight behind what we're trying to do is in the drug discovery and development. we Im in our company.

**OTC Markets**

And what is GB Science's main therapeutic focus?

**Andrea Small-Howard**

Sure, our lead program is in Parkinson's disease. We also have a chronic pain and an anti-inflammatory in our pipeline, there's actually five different conditions in our pipeline. Um, so in addition to Parkinson's and chronic pain, um, and the anti-inflammatory that I mentioned before, we also have a heart disease and an anxiety formula in the pipeline.

**OTC Markets**

So how does GB differentiate itself in the crowded field of biopharmaceuticals?

**Andrea Small-Howard**

So we're one of just a handful of companies that's really interested in looking at traditional medicines and plant-based formulations. But we believe that this is our strength and in addition, we're not just going and looking for the magic bullet in a plant. We're looking for mixtures because one of the things that we noted is that western medicine usually involves single active ingredient drugs whereas if you look at traditional medicines, there's usually multiple actives that are working in concert and so our goal is to reduce the complexity of traditional medicines down to just a few compounds that we're calling minimum essential mixtures. So in other words of the hundreds of ingredients that are in a traditional medicine, we're looking for those 3-5 ingredients that work together and we can demonstrate that by having them in a formulation together. They're more effective than if you used them individually, does that make sense?

**OTC Markets**

Absolutely it does. So go on and talk about your Pharoah's AI-enabled drug discovery platform that you recently announced and how it's shaping your business.

**Andrea Small-Howard**

Yes, absolutely we're very excited about the Pharaoh's Platform. The big idea behind Pharaoh's is that we've been able to take multiple traditional medical systems and plug all that information into a single database that we can search across and by doing that we're able to gain insights from these different formulations that have been used for thousands of years in different places in the world and one of the big ideas behind how Pharaoh is different than some of the other programs that might be out there is that we're looking for areas of overlap meaning for example, for pain, most cultures have formulations that have that are for pain and if we look at the areas of similarity in the molecules, we believe that if these things that are happening independently in time overlap then there is more likely to be real therapeutics then just they're in those formulations by chance, if that makes sense. So we think that this is a powerful approach and um, let's face it, they AI is really beginning to shape who we are as a society and I think that you're going to see more and more uses of AI and so drug discovery, just one of

the most recent applications of this powerful technology that's shaping our world right now.

**OTC Markets**

What's next in 2023 and beyond for the company?

**Andrea Small-Howard**

Absolutely, so what we believe is that this is gonna be our year, where we get the enabling studies done for our Parkinson's formulations and we get those into our first in-human trial or oh aiming for the fews and first and human trial to begin. Actually, say Q1 of 2024 but this is the year that we complete the data that's required for doing our filing to get to that first in-human trial. In addition, we've got a chronic pain formulation that is also coming right behind it. As far as we're looking towards the clinic, we're really excited also about our anxiety formulations that are based on a plant called Kava and it's been used in eight of the pacific Asian cultures for thousands of years.

**OTC Markets**

Why was it important for GB Sciences to trade on the OTCQB marketplace?

**Andrea Small-Howard**

We believe it gives us the reach of the flexibility that we need to be able to um offer this exciting platform of products and services, ah to the investment public.

**OTC Markets**

Well, very exciting. We're happy to have you and we look forward to you know, seeing the journey of your story. Great talking with you Andrea. GB Sciences trades under the symbol GBLX on our OTCQB Venture Market.

**Andrea Small-Howard**

Thank you so much.

*\*This is an autogenerated transcript and may contain typos.*